Sec Form 4 Filing - Scott John K Jr. @ NAVIDEA BIOPHARMACEUTICALS, INC. - 2022-08-30

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Scott John K Jr. 2. Issuer Name and Ticker or Trading Symbol NAVIDEA BIOPHARMACEUTICALS, INC. [ NAVB] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 4995 BRADENTON AVE., SUITE 240 3. Date of Earliest Transaction (MM/DD/YY) 08/30/2022 (Street) DUBLIN, OH43017 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/31/2022 A 2,500( 1 )( 2 ) A $ 0 8,103,395 D Common Stock 10,139 I By spouse and children( 3 ) Series G Redeemable Preferred Stock 3,260 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series F Redeemable Convertible Preferred Stock $ 0.8 08/30/2022 S( 4 ) 1,740 04/10/2022 ( 5 ) Common Stock 2,175,000 $ 1,379.31( 4 ) 0 D Series I Convertible Preferred Stock $ 0.45 08/30/2022 P( 6 ) 2,400 08/30/2022 ( 7 ) Common Stock 5,332,800 ( 6 ) 2,400 D Warrant to Purchase Common Stock $ 0.5 08/30/2022 P( 6 ) 2,400 08/30/2022 08/30/2027 Common Stock 5,332,800 ( 6 ) 2,400 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Scott John K Jr. 4995 BRADENTON AVE., SUITE 240 DUBLIN, OH43017 X X Signatures /s/ Erika L. Eves for John K. Scott, Jr. by power of attorney 09/01/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of monthly non-employee director fees. ( 2 )Issuance deferred at the request of the Reporting Person. ( 3 )Includes 2,639 shares of Common Stock owned by the Reporting Person's spouse and 7,500 shares of Common Stock owned by the Reporting Person's children. The Reporting Person may be deemed to have shared voting and/or dispositive power with respect to such shares. ( 4 )Series F Redeemable Convertible Preferred Stock, par value $.001 per share, was surrendered to pay the subscription price for the units purchased in the Rights Offering. The fair market value of the Series F Redeemable Convertible Preferred Stock surrendered in the Rights Offering was determined by the Issuer's board of directors based on an independent appraisal obtained by the Issuer. ( 5 )Series F Redeemable Convertible Preferred Stock, par value $.001 per share, was convertible at any time and had no expiration date. ( 6 )The Reporting Person acquired the Series I Convertible Preferred Stock and Warrants to Purchase Common Stock pursuant to the exercise of subscription rights in connection with the Issuer's previously announced rights offering ("Rights Offering"), as disclosed in the Registration Statement on Form S-1, as amended, and Prospectus Supplement No. 1 filed by the Issuer with the Securities and Exchange Commission. Pursuant to the Rights Offering, the Reporting Person purchased units at a subscription price of $1,000 per unit, with each unit consisting of one (1) share of Series I Convertible Preferred Stock and one (1) Warrant to Purchase 2,222 shares of Common Stock. ( 7 )Series I Convertible Preferred Stock, par value $.001 per share, is convertible at any time and has no expiration date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.